Despite tremendous advancements in the field, our understanding of mild cognitive impairment (MCI) and Alzheimer’s disease (AD) among Mexican Americans remains limited.
Objective:
The aim of this study was to characterize MCI and dementia among Mexican Americans and non-Hispanic whites.
Methods:
Baseline data were analyzed from n = 1,705 (n = 890 Mexican American; n = 815 non-Hispanic white) participants enrolled in the Health and Aging Brain Study-Health Disparities (HABS-HD).
Results:
Among Mexican Americans, age (OR = 1.07), depression (OR = 1.09), and MRI-based neurodegeneration (OR = 0.01) were associated with dementia, but none of these factors were associated with MCI. Among non-Hispanic whites, male gender (OR = 0.33), neighborhood deprivation (OR = 1.34), depression (OR = 1.09), and MRI-based neurodegeneration (OR = 0.03) were associated with MCI, while depression (OR = 1.09) and APOEɛ4 genotype (OR = 4.38) were associated with dementia.
Conclusion:
Findings from this study revealed that the demographic, clinical, sociocultural and biomarker characteristics of MCI and dementia are different among Mexican Americans as compared to non-Hispanic whites.
MatthewsKA, XuW, GagliotiAH, HoltJB, CroftJB, MackD, McGuireLC (2019) Racial and ethnic estimates of Alzheimer’s disease and related dementias in the United States (2015–2060) in adults aged≥65 years. Alzheimers Dement15, 17–24.
5.
CamposM, EdlandSD, PeavyGM (2013) Exploratory study of apolipoprotein E ɛ4 genotype and risk of Alzheimer’s disease in Mexican Hispanics. J Am Geriatr Soc61, 1038–1040.
O’BryantSE, JohnsonL, BalldinV, EdwardsM, BarberR, WilliamsB, DevousM, CushingsB, KneblJ, HallJ (2013) Characterization of Mexican Americans with mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis33, 373–379.
8.
O’BryantSE, JohnsonL, EdwardsM, SoaresH, DevousMD, RossS, RohlfingG, HallJ (2013) The link between C-reactive protein and Alzheimer’s disease among Mexican Americans. J Alzheimers Dis34, 701–706.
9.
O’BryantSE, ZhangF, PetersenM, HallJR, JohnsonLA, YaffeK, MasonD, BraskieM, BarberRA, RissmanRA, MapstoneM, MielkeMM, TogaAW (2022) A blood screening tool for detecting mild cognitive impairment and Alzheimer’s disease among community-dwelling Mexican Americans and non-Hispanic Whites: A method for increasing representation of diverse populations in clinical research. Alzheimers Dement18, 77–87.
10.
O’BryantS, PetersenM, HallJ, JohnsonL, YaffeK, BraskieM, TogaAW, RissmanRA (2022) Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: Results from the HABLE study. Alzheimers Dement18, 240–250.
11.
O’BryantSE, JohnsonLA, BarberRC, BraskieMN, ChristianB, HallJR, HazraN, KingK, KothapalliD, LargeS, MasonD, MatsiyevskiyE, McCollR, NandyR, PalmerR, PetersenM, PhilipsN, RissmanRA, ShiY, TogaAW, VintimillaR, VigR, ZhangF, YaffeK (2021) The Health & Aging Brain among Latino Elders (HABLE) study methods and participant characteristics. Alzheimers Dement (Amst)13, e12202.
12.
HallJR, JohnsonLA, ZhangF, PetersenM, TogaAW, ShiY, MasonD, RissmanRA, YaffeK, O’BryantSE (2021) Using fractional anisotropy imaging to detect mild cognitive impairment and Alzheimer’s disease among Mexican Americans and Non-Hispanic whites: A HABLE study. Dement Geriatr Cogn Disord50, 266–273.
13.
O’BryantSE, ZhangF, PetersenM, HallJ, JohnsonLA, YaffeK, BraskieM, RissmanRA, VigR, TogaAW (2022) Neurodegeneration from the AT(N) framework is different among Mexican Americans compared to non-Hispanic Whites: A Health & Aging Brain among Latino Elders (HABLE) Study. Alzheimers Dement (Amst)14, e12267.
14.
MarinG, SabogalF, MarinBV, Otero-SabogalR, Perez-StableEJ (1987) Development of a short acculturation scale for Hispanics. Hisp J Behav Sci9, 183–205.
O’BryantSE, EdwardsM, JohnsonL, HallJ, GamboaA, O’jileJ (2018) Texas Mexican American adult normative studies: Normative data for commonly used clinical neuropsychological measures for English- and Spanish-speakers. Dev Neuropsychol43, 1–26.
17.
GonzálezHM, MungasD, HaanMN (2002) A verbal learning and memory test for English- and Spanish-speaking older Mexican-American adults. Clin Neuropsychol16, 439–451.
18.
SierraSanjurjo N, MontañesP, Sierra MatamorosFA, BurinD (2015) Estimating intelligence in Spanish: Regression equations with the Word Accentuation Test and demographic variables in Latin America. Appl Neuropsychol Adult22, 252–261.
19.
MorrisJC (1997) Clinical dementia rating: A reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr1, 173–176.
20.
KindAJH, BuckinghamWR (2018) Making neighborhood-disadvantage metrics accessible — The Neighborhood Atlas. N Engl J Med378, 2456–2458.
21.
KindAJH, JencksS, BrockJ, YuM, BartelsC, EhlenbachW, GreenbergC, SmithM (2014) Neighborhood socioeconomic disadvantage and 30-day rehospitalization: A retrospective cohort study. Ann Intern Med161, 765–774.
22.
HuntJF v, VogtNM, JonaitisEM, BuckinghamWR, KoscikRL, ZuelsdorffM, ClarkLR, GleasonCE, YuM, OkonkwoO, JohnsonSC, AsthanaS, BendlinBB, KindAJH (2021) Association of neighborhood context, cognitive decline, and cortical change in an unimpaired cohort. Neurology96, e2500–e2512.
23.
HuntJFV, BuckinghamW, KimAJ, OhJ, VogtNM, JonaitisEM, HuntTK, ZuelsdorffM, PowellR, NortonD, RissmanRA, AsthanaS, OkonkwoOC, JohnsonSC, KindAJH, BendlinBB (2020) Association of neighborhood-level disadvantage with cerebral and hippocampal volume. JAMA Neurol77, 451–460.
24.
PowellWR, BuckinghamWR, LarsonJL, VilenL, YuM, SalamatMS, BendlinBB, RissmanRA, KindAJH (2020) Association of neighborhood-level disadvantage with Alzheimer disease neuropathology. JAMA Netw Open3, e207559.
25.
BohannonRW (2006) Reference values for the timed up and go test: A descriptive meta-analysis. J Geriatr Phys Ther29, 64–68.
26.
TreacyD, HassettL (2018) The Short Physical Performance Battery. J Physiother64, 61.
27.
O’BryantSE, GuptaV, HenriksenK, EdwardsM, JerominA, ListaS, BazenetC, SoaresH, LovestoneS, HampelH, MontineT, BlennowK, ForoudT, CarrilloM, Graff-RadfordN, LaskeC, BretelerM, ShawL, TrojanowskiJQ, SchupfN, RissmanRA, FaganAM, OberoiP, UmekR, WeinerMW, GrammasP, PosnerH, MartinsR (2015) Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research. Alzheimers Dement11, 549–560.
28.
JackCR, WisteHJ, TherneauTM, WeigandSD, KnopmanDS, MielkeMM, LoweVJ, VemuriP, MachuldaMM, SchwarzCG, GunterJL, SenjemML, Graff-RadfordJ, JonesDT, RobertsRO, RoccaWA, PetersenRC (2019) Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA321, 2316–2325.
O’BryantSE, LacritzLH, HallJ, WaringSC, ChanW, KhodrZG, MassmanPJ, HobsonV, CullumCM (2010) Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the National Alzheimer’s Coordinating Center database. Arch Neurol67, 746–749.
31.
O’BryantSE, WaringSC, CullumCM, HallJ, LacritzL, MassmanPJ, LupoPJ, ReischJS, DoodyR (2008) Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: A Texas Alzheimer’s research consortium study. Arch Neurol65, 1091–1095.
32.
O’BryantSE, PetersenM, HallJ, JohnsonLA (2022) Medical comorbidities and ethnicity impact plasma Alzheimer’s disease biomarkers: Important considerations for clinical trials and practice. Alzheimers Dementdoi: 10.1002/alz.12647.
33.
O’BryantSE, ZhangF, PetersenM, JohnsonL, HallJ, RissmanRA (2021) A precision medicine approach to treating Alzheimer’s disease using rosiglitazone therapy: A biomarker analysis of the REFLECT Trials. J Alzheimers Dis81, 557–568.
